Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Target Price at $8.50

Posted by Francis Steltz on Sep 8th, 2026

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Free Report) has earned an average rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $8.50.

NRSN has been the topic of a number of analyst reports. HC Wainwright began coverage on NeuroSense Therapeutics in a report on Thursday, September 3rd. They issued a “buy” rating on the stock. Weiss Ratings downgraded NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th.

Read Our Latest Stock Report on NRSN

NeuroSense Therapeutics Price Performance

Shares of NeuroSense Therapeutics stock opened at $0.51 on Tuesday. The firm has a market cap of $19.29 million, a price-to-earnings ratio of -0.95 and a beta of 1.60. NeuroSense Therapeutics has a 52-week low of $0.25 and a 52-week high of $1.98. The company’s 50-day simple moving average is $0.55 and its 200-day simple moving average is $0.71.

Insiders Place Their Bets

In related news, CEO Alon Ben-Noon bought 250,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the transaction, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Or Eisenberg purchased 250,000 shares of the stock in a transaction dated Tuesday, June 16th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the purchase, the chief financial officer owned 1,504,050 shares in the company, valued at approximately $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 27.40% of the company’s stock.

Institutional Trading of NeuroSense Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Yorkville Advisors Global LP acquired a new stake in shares of NeuroSense Therapeutics during the 4th quarter valued at approximately $77,000. Squarepoint Ops LLC grew its holdings in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the period. Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics in the 2nd quarter worth approximately $54,000. Finally, Two Sigma Investments LP purchased a new position in NeuroSense Therapeutics in the 3rd quarter valued at approximately $26,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

(Get Free Report)

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.